Management of Chronic Hepatitis C Virus Infection in HIV-Infected Patients

Pol, Stanislas; Soriano, Vincent
July 2008
Clinical Infectious Diseases;7/1/2008, Vol. 47 Issue 1, p94
Academic Journal
The managment of chronic hepatitis C virus infection in patients coinfected with the human immunodeficiency virus poses a significant challenge. Treatment is influenced by a number of viral and host characteristics, including hepatitis C virus genotype, baseline viremia, and adherence to medication regimen. Accelerated progression of liver disease, immunodeficiency, and hepatotoxicity of antiretroviral drugs are additional concerns in coinfected patients. According to the results of 5 randomized clinical trials, 27%-55% of coinfected patients who received therapy with pegylated interferon-alfa and ribavirin attained a sustained virologic response. These studies also confirm the importance of early virologic response as a predictor of treatment outcome and reveal the considerable proportion of patients who experience hematologic tolerability issues. Effective management strategies that encompass patient and viral factors are necessary to improve the long-term outlook for coinfected patients.


Related Articles

  • Thalidomide Treatment for Refractory HIV-Associated Colitis: A Case Series. Johnson, Leann; Jarvis, Joseph N.; Wilkins, Edmund G. L.; Hay, Phillip E. // Clinical Infectious Diseases;7/1/2008, Vol. 47 Issue 1, p133 

    Thalidomide has been used as a treatment for various human immunodeficiency virus (HIV)-associated and non-HIV-associated illnesses, generally in cases in which inflammatory disease is refractory to standard therapy. Here, we discuss the successful use of thalidomide in 3 patients with severe,...

  • High Frequency of Advanced Hepatic Disease among HIV/HCV Co-Infected Patients in Cambodia: The HEPACAM Study (ANRS 12267). Lerolle, Nathalie; Limsreng, Setha; Fournier-Nicolle, Isabelle; Sowath Ly; Nouhin, Janin; Guillard, Bertrand; Ken, Sreymom; Dulioust, Anne; Pichit Khuon; Delfraissy, Jean-François; Vara Ouk; Segeral, Olivier // Journal of AIDS & Clinical Research;2012, Vol. 3 Issue 6, Special section p1 

    Background: Little is known about HIV/Hepatitis C Virus (HCV) co-infection in resource-limited countries, although chronic HCV infection is one of the most relevant comorbidities in HIV population. The aim of this study was to determine the severity of liver disease in a cohort of HIV/HCV...

  • ALLY 2. Hoyle, Brian; Sherman, Kenneth // MD Conference Express;Jul2015, Vol. 15 Issue 14, p9 

    Results of the ALLY 2 trial involving more than 200 patients co-infected with HIV/HCV shows the efficacy and safety of the combined 12-week use of daclatasvir and sofosbuvir, with sustained virologic response for 12 weeks of 97% after a 12-week treatment. The benefit for HCV infection does not...

  • HIV and the kidney in the acute medical unit. Booth, John W.; Post, Frank A. // Clinical Medicine;Dec2015, Vol. 15 Issue 6, p571 

    Acute kidney injury (AKI) is encountered commonly in HIV-positive patients admitted to the acute medical unit. The spectrum of AKI has changed in the era of combination anti-retroviral therapy, and now includes adverse effects of commonly used anti-retroviral drugs in addition to traditional...

  • HIV Infection�Associated Tuberculosis: The Epidemiology and the Response. Getahun, Haileyesus; Gunneberg, Christian; Granich, Reuben; Nunn, P0ul // Clinical Infectious Diseases;5/15/2010 Supplement 3, Vol. 50, pS201 

    Of the 33.2 million persons infected with human immunodeficiency virus (HIV), one-third are estimated to also be infected with Mycobacterium tuberculosis. In 2008, there were an estimated 1.4 million new cases of tuberculosis (TB) among persons with HIV infection, and TB accounted for 26% of...

  • Lipodystrophy Severity Does Not Contribute to HAART Nonadherence. Collins, Evan J.; Burgoyne, Robert W.; Wagner, Cheryl A.; Abbey, Susan E.; Halman, Mark H.; Nur, Margaret L.; Walmsley, Sharon L. // AIDS & Behavior;May2006, Vol. 10 Issue 3, p273 

    Lipodystrophy severity among 77 people living with HIV/AIDS (PHA) with body fat redistribution was not related to antiretroviral adherence including doses missed during the previous month, categorical rating of maximal adherence, and the PMAQ7 adherence behavior scale. Two thirds of the sample...

  • HIV associated nephropathy: a treatable condition. Brook, M Gary; Miller, Robert F; Brook, M G; Miller, R F // Sexually Transmitted Infections;Apr2001, Vol. 77 Issue 2, p97 

    Objectives: To describe current knowledge on the aetiology, pathology, diagnosis, and treatment of HIV associated nephropathy.Methods: A Medline search was performed using the key words "HIV," "nephropathy," "renal," and "kidney." A further search was performed for each...

  • Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients. Plaza, Zulema; Soriano, Vincent; Gonzalez, Maria del Mar; Di Lello, Federico A.; Macias, Juan; Labarga, Pablo; Pineda, Juan Antonio; Poveda, Eva // Journal of Antimicrobial Chemotherapy (JAC);Dec2011, Vol. 66 Issue 12, p2838 

    Objectives Assessment of the impact of antiretroviral drugs on the variability of hepatitis C virus (HCV) NS5B polymerase in HIV/HCV co-infected individuals. Methods HCV NS5B polymerase was sequenced from plasma at baseline and at the end of follow-up in HIV/HCV co-infected individuals on a...

  • Degree of Viral Decline Early in Treatment Predicts Sustained Virological Response in HCV-HIV Coinfected Patients Treated with Peginterferon Alfa-2a and Ribavirin. Rodriguez-Torres, M.; Torriani, F.; Rockstroh, J.; Depamphilis, J.; Carosi, G.; Dieterich, D.T. // HIV Clinical Trials;Jan/Feb2010, Vol. 11 Issue 1, p1 

    Background: In hepatitis C virus (HCV) monoinfection, the on-treatment virological response at Weeks 4 and 12 is a strong predictor of treatment outcomes.Methods: In a retrospective analysis, we examined these responses in 289 HIV-HCV coinfected patients treated with Peg-IFN alfa-2a /ribavirin...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics